Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA
NEW YORK, October 4, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), Sanofi (NYSE: SNY), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Merck & Co. Inc. Research Report
On October 1, 2013, Merck & Co. Inc. (Merck) announced the intention to move its global headquarters from Whitehouse Station, N.J., to its existing facilities in Kenilworth, N.J. Merck reported that based on the evaluation of its real estate needs in the state, it has determined that it could achieve greater cost savings and operational synergies by closing both its Summit campus and its main Whitehouse Station facility. The Company's Animal Health and Consumer Care divisions currently located in Summit will be relocated to another facility in New Jersey, while certain manufacturing, laboratory and other functions currently located in Summit will be relocated to other facilities in New Jersey or Pennsylvania. Merck expects to begin the transition in 2014 and complete by 2015. The Company stated that these plans are part of its global initiative to sharpen its commercial and R&D focus and reduce costs, including the size of its workforce and global real estate footprint. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/430d_MRK]
--
GlaxoSmithKline plc Research Report
On September 27, 2013, GlaxoSmithKline plc (GSK) announced its partnership with Barclays to increase access to affordable healthcare and medicines for people in Zambia, while helping to create improved economic conditions for growth. GSK reported that the partnership aims to help remove financial barriers to healthcare access, while supporting small business development and job creation. Sir Andrew Witty, CEO of GSK, commented, "Though prospects for growth are improving, Zambia still experiences significant healthcare challenges. By combining our specific resources and skills with those of Barclays, we can help unblock financial barriers and enhance government efforts to help increase access to affordable healthcare. Good health is vital for people to live more productive lives, which in turn will help to create the right conditions for Zambia's economic development and lead to a more prosperous society." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]
--
Sanofi Research Report
On September 27, 2013, Sanofi announced that it has renewed its cooperation protocol with Aviesan, the French National Alliance for Life Sciences and Health, for a period of three years. According to Sanofi, the renewal of the agreement aims to contribute to the development of new treatments that target unmet medical needs, including those in the field of rare diseases, to participate to the excellence and consolidation of research in French industry on an international level. The Company reported that a special emphasis will be put on translational research projects that bring together clinical and medical teams with fundamental research teams to translate research successes into medical advances. Sanofi reported that under the new protocol, the research teams of both the Companies will spur the development of technology platforms to finance the work of researchers, CIFRE fellows, post-docs, and staff secondment. The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]
--
Intercept Pharmaceuticals, Inc. Research Report
On October 1, 2013, Intercept Pharmaceuticals, Inc. (Intercept) announced that two analyses by the Global Primary Biliary Cirrhosis (PBC) Study Group (PBC Supergroup) have been accepted for oral presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on November 1 to 5, 2013 in Washington, D.C. Intercept revealed that data from over 3,895 PBC patients collected and pooled by an independent group of 15 academic medical centers across eight countries have been analyzed by the PBC Supergroup. The Company stated that the analyses are expected to further confirm that the surrogate biochemical endpoint used by Intercept in its ongoing Phase 3 POISE trial (i.e., alkaline phosphatase (ALP) < 1.67x upper limit of normal and normal bilirubin) is strongly predictive of adverse clinical outcomes in PBC patients. Intercept further informed that the two abstracts from the PBC Supergroup are available at the AASLD website. The Full Research Report on Intercept Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b477_ICPT]
--
KYTHERA Biopharmaceuticals, Inc. Research Report
On September 19, 2013, KYTHERA Biopharmaceuticals, Inc. (KYTHERA) announced the appointment of Hospira's CEO F. Michael (Mike) Ball to its Board of Directors. Keith Leonard, President and CEO of KYTHERA, commented, "Mike's breadth of experience in developing the global aesthetic market and leading product brands such as BOTOX Cosmetic®, JUVEDERM® and Latisse® make him an ideal addition to the KYTHERA Board." Leonard added, "We are thrilled to have him on board. His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine." The Full Research Report on KYTHERA Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b90a_KYTH]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsCorner.com
SOURCE Analysts' Corner
Share this article